This HTML5 document contains 187 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n12http://dx.doi.org/10.1007/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
n13https://scigraph.springernature.com/pub.10.1007/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q33807228
rdf:type
wikibase:Item
schema:description
mokslinis straipsnis scientific article 2011년 논문 artigo científico (publicado na 2011) artículo científico publicado en 2011 naučni članak vitenskapelig artikkel научна статия 2011年論文 мақолаи илмӣ artigo científico 2011年論文 tudományos cikk wissenschaftlicher Artikel 2011年论文 teaduslik artikkel บทความทางวิทยาศาสตร์ article scientifique (publié 2011) 2011年論文 научни чланак vitskapeleg artikkel artikull shkencor bilimsel makale مقالهٔ علمی videnskabelig artikel (udgivet 2011) bài báo khoa học ২০১১-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ επιστημονικό άρθρο 2011年论文 2011 թուականի Յունիսին հրատարակուած գիտական յօդուած научни чланак tieteellinen artikkeli 2011年论文 articolo scientifico scienca artikolo 2011年の論文 سائنسی مضمون мақолаи илмӣ article científic artykuł naukowy სამეცნიერო სტატია научная статья artículu científicu espublizáu en 2011 2011年論文 2011 nî lūn-bûn article scientific 2011 թվականի հունիսին հրատարակված գիտական հոդված vědecký článek 2011年论文 articol științific 2011年論文 vedecký článok wetenschappelijk artikel artikulong pang-agham наукова стаття, опублікована в червні 2011 vetenskaplig artikel مقالة علمية artigo científico (publicado na 2011) מאמר מדעי 2011年论文 2011年论文
p:P577
wds:Q33807228-22B45ED0-D9E5-427C-9A55-6BB40320E35F
wdt:P577
2011-06-01T00:00:00Z
p:P2888
wds:Q33807228-1B6C7218-BD4F-4DD9-AD87-A618B02C72F0
wdt:P2888
n13:s11910-011-0184-0
p:P2860
wds:Q33807228-233FF491-0713-45ED-96E8-F5C413BBD967 wds:Q33807228-38AAF4EF-E9CE-4D61-AED7-A387D961F945 wds:Q33807228-07DE42B6-D93A-4778-ADC4-E5CBFC886291 wds:Q33807228-1D0A9B1D-6203-4C8E-89B3-D6FF26334B43 wds:Q33807228-3ED1C673-1059-4537-ADBB-729AEDCB985F wds:Q33807228-448EF16C-68BE-4F94-8AEA-BEABA484D313 wds:Q33807228-465F5F43-0867-4707-9553-5960D823DB2C wds:Q33807228-4C6344B0-2FD4-4E81-B8BB-0669F681724B wds:Q33807228-05ADB938-18BF-4309-9BCA-DFFF921EE440 wds:Q33807228-05FBB986-B9C9-4E29-A286-DF8DAA5F181F wds:Q33807228-06F3BACB-DC2F-4D9C-802E-CDF072595673 wds:Q33807228-BC5E509A-643F-4D5B-926F-42975177F4FB wds:Q33807228-BE241CD4-AFFE-41C1-B544-18E361405E1C wds:Q33807228-BFF15C81-39DE-4455-B056-75E6D767C378 wds:Q33807228-C0038B21-B1D7-4135-B637-5A71A5DFE191 wds:Q33807228-A48D1AF1-93B7-466D-A846-5EC88DD8AB8C wds:Q33807228-B39ED63D-0D8C-4416-8E2E-26D28B62A94B wds:Q33807228-B7A23974-87E4-4F26-B430-78A3E336822C wds:Q33807228-B9BB5F49-E06A-4757-9703-B825346C9539 wds:Q33807228-CE796B0B-B2CE-431F-B1EE-B10FDE3DB9EE wds:Q33807228-D8770CF0-C638-49B0-A975-84AE90BAAB27 wds:Q33807228-E120E17B-22F1-459F-BF73-3025F9BAD94F wds:Q33807228-C15DFF8F-ACAC-4CAB-942D-B9AA48FC7C2C wds:Q33807228-C86E59C8-C410-4FE7-A6DC-E0A0C6D96136 wds:Q33807228-CA772856-4B7D-45F1-81D0-1D5C58B3165C wds:Q33807228-64FA3B69-1346-4932-A88A-3A423875A374 wds:Q33807228-6D861A2B-9710-4882-B172-F0AADEFAC43C wds:Q33807228-7033663B-04E2-4302-8E5A-A86BB5E15918 wds:Q33807228-72D71E94-0B6A-4E73-9EB0-1E52EB2B0EBF wds:Q33807228-5E3FCCCF-D66F-4DB1-B9B3-38E0CD6CD280 wds:Q33807228-60130BC9-77FD-4675-8FBA-28072903521E wds:Q33807228-95770945-E911-4643-AD86-22E863A7CFD5 wds:Q33807228-96E826F0-7FF4-4D7A-8DD0-7C66CDEA364F wds:Q33807228-9818A7EC-C6C8-4E30-8C38-CC5DD4510989 wds:Q33807228-A26A3769-A734-424D-97C7-F4026FC5EB16 wds:Q33807228-77118B80-FACA-4F2B-99A8-CA560E144886 wds:Q33807228-90BB61BC-ED0F-4789-8D63-CA56E220AAF2 wds:Q33807228-94320052-6993-470F-9373-29602FB15E68 wds:Q33807228-FDEE2839-5B50-4F3F-94FB-452729A6CD28 wds:Q33807228-F14BFA32-1622-48D2-8C7B-9D1D2BB3E616 wds:Q33807228-FBBD7C06-4F83-4D18-BF72-DC3053CC382E
wdt:P2860
wd:Q31148416 wd:Q42830150 wd:Q34997337 wd:Q46942082 wd:Q40479307 wd:Q46079015 wd:Q30490422 wd:Q37284239 wd:Q29617568 wd:Q48789443 wd:Q35698555 wd:Q33382596 wd:Q24608039 wd:Q44485999 wd:Q33710967 wd:Q55463706 wd:Q24292724 wd:Q44781447 wd:Q30661157 wd:Q42817299 wd:Q37284341 wd:Q37325097 wd:Q33424257 wd:Q34939141 wd:Q29615445 wd:Q42168743 wd:Q55464144 wd:Q43236738 wd:Q48368209 wd:Q40050768 wd:Q45936256 wd:Q37029719 wd:Q33759231 wd:Q46222206 wd:Q48271471 wd:Q46332916 wd:Q37325086 wd:Q33518926 wd:Q48789795 wd:Q48305390 wd:Q33731698
p:P2093
wds:Q33807228-E8D529E1-DB3E-4A32-873C-A1A9F3DA05A1
wdt:P2093
Markus Weiler
rdfs:label
Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence
skos:prefLabel
Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence
schema:name
Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence
p:P50
wds:Q33807228-FAA3471F-29B2-4B4A-916F-51B31D745041 wds:Q33807228-5CCAE2A4-D8B4-4E8C-8DB9-7723A1341278 wds:Q33807228-C797B432-8FBC-46CB-9193-712B8C0497F0
wdt:P50
wd:Q2591750 wd:Q98154405 wd:Q2779469
p:P1476
wds:Q33807228-5ABA2343-80BC-4BFC-BC86-AFA37D28BBE6
wdt:P1476
Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence
p:P304
wds:Q33807228-072AEA4C-837B-43E3-9A12-E10E95AB7423
wdt:P304
305-312
p:P31
wds:Q33807228-36CA654B-5DBB-4FE7-ADBE-13A52826024E wds:Q33807228-c3cb2c6c-ebf2-470e-835a-c2aab7fa8660
wdt:P31
wd:Q13442814 wd:Q7318358
p:P698
wds:Q33807228-D663D68A-CDB7-413B-B133-91F5021FE05C
wdtn:P698
n11:21279815
wdt:P698
21279815
p:P1433
wds:Q33807228-9069E57B-A27E-47A2-9729-831D13780544
wdt:P1433
wd:Q18206211
p:P433
wds:Q33807228-5BB1A79C-3D58-472B-B739-65DB420CF098
p:P478
wds:Q33807228-62971D78-A1E4-4A45-AFD8-66462A27BDC9
wdt:P433
3
wdt:P478
11
p:P356
wds:Q33807228-52698CF4-0F69-429F-A967-B15E1773BE2C
wdtn:P356
n12:S11910-011-0184-0
wdt:P356
10.1007/S11910-011-0184-0
p:P6179
wds:Q33807228-5B46A960-3583-488D-87D2-D5368ADC85CC
wdt:P6179
1005014853